We are live on ! Find out more
FM

Frazier Management Portfolio holdings

AUM $1.12M
1-Year Est. Return 151.58%
This Fund
S&P 500
This Quarter Est. Return
+34.56%
1 Year Est. Return
+151.58%
3 Year Est. Return
+408.4%
5 Year Est. Return
+1,802.6%
10 Year Est. Return
–
AUM
$1.99M
AUM Growth
-$1.3B
Cap. Flow
-$1.31B
Cap. Flow %
-65,665.63%
Top 10 Hldgs %
100%
Holding
43
New
–
Increased
–
Reduced
2
Closed
41

Top Buys

No buys this quarter

Top Sells

Rank Stock Value
1
ARQT icon
Arcutis Biotherapeutics
ARQT
+$175M
2
PHAT icon
Phathom Pharmaceuticals
PHAT
+$115M
3
IMGO
Imago BioSciences, Inc. Common stock
IMGO
+$70.4M
4
SNDX icon
Syndax Pharmaceuticals
SNDX
+$60.7M
5
GRTS
Gritstone bio, Inc. Common Stock
GRTS
+$60M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SRRK icon
26
Scholar Rock
SRRK
$7.22B
– –
-156,000
Closed -$3.88M
STRO icon
27
Sutro Biopharma
STRO
$353M
– –
-177,648
Closed -$26.4M
TARS icon
28
Tarsus Pharmaceuticals
TARS
$3.16B
– –
-1,417,157
Closed -$31.9M
TYRA icon
29
Tyra Biosciences
TYRA
$1.56B
– –
-1,250,000
Closed -$17.6M
VRDN icon
30
Viridian Therapeutics
VRDN
$2.71B
– –
-1,505,200
Closed -$29.8M
GRTS
31
DELISTED
Gritstone bio, Inc. Common Stock
GRTS
– –
-4,667,242
Closed -$60M
ALPN
32
DELISTED
Alpine Immune Sciences Inc
ALPN
– –
-1,784,913
Closed -$24.7M
GRCL
33
DELISTED
Gracell Biotechnologies Inc. American Depositary Shares
GRCL
– –
-1,654,938
Closed -$10M
PRDS
34
DELISTED
Pardes Biosciences, Inc. Common Stock
PRDS
– –
-2,457,507
Closed -$40.2M
MTEM
35
DELISTED
Molecular Templates, Inc.
MTEM
– –
-91,603
Closed -$5.39M
KDNY
36
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
– –
-2,371,918
Closed -$38.7M
ISEE
37
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
– –
-1,838,402
Closed -$30.7M
APTX
38
DELISTED
Aptinyx Inc. Common Stock
APTX
– –
-1,883,244
Closed -$5.03M
TCDA
39
DELISTED
Tricida, Inc. Common Stock
TCDA
– –
-1,783,893
Closed -$17.1M
IMGO
40
DELISTED
Imago BioSciences, Inc. Common stock
IMGO
– –
-2,971,274
Closed -$70.4M
FLACU
41
DELISTED
Frazier Lifesciences Acquisition Corporation Unit
FLACU
– –
-1,501,000
Closed -$14.9M
EPZM
42
DELISTED
Epizyme, Inc
EPZM
– –
-739,369
Closed -$1.85M
NBRV
43
DELISTED
Nabriva Therapeutics plc Ordinary Shares Ireland
NBRV
– –
-17,026
Closed -$255K
1
2

Similar funds

ACMV
August Capital Management VI Palo Alto, California $1.39M AUM
FRCMI
First Round Capital Management III Philadelphia, Pennsylvania $418K AUM
DB
DCVC Bio Palo Alto, California $313K AUM
NAM
Newfleet Asset Management Hartford, Connecticut $2.05M AUM 27.28% 1-Year Est. Return
AP
Atlas Principals Charlotte, North Carolina $2.19M AUM 56.71% 1-Year Est. Return
ID
Inspire Developers Forest Hills, New York $4.07M AUM
CI
CMT Investments Chicago, Illinois $5M AUM 15.27% 1-Year Est. Return
DIF
Discovery Investment Fund Singapore $6.98M AUM

Frazier Management's Q1 2022 Portfolio in Review

As of Q1 2022, Frazier Management held 43 positions worth $1.99M, down 100% from $1.3B the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Frazier Management withdrew a net $1.31B in Q1 2022, closing 41 positions and reducing 2 holdings. Its most notable exit was Arcutis Biotherapeutics, an estimated $175M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 99% a quarter earlier.

  • Frazier Management's biggest Q1 2022 reduction was Sierra Oncology, Inc. Common Stock, cutting an estimated $34.7M.
  • Frazier Management fully exited Arcutis Biotherapeutics in Q1 2022, selling an estimated $175M.
  • Frazier Management's ten largest holdings make up 100% of its $1.99M portfolio in Q1 2022.
  • Frazier Management opened 0 new positions and closed 41 in Q1 2022.
  • Frazier Management's portfolio value fell 100% quarter-over-quarter to $1.99M.

Based on Frazier Management's 13F filing for Q1 2022, filed 13 May 2022.